MELINTA THERAPEUTICS, INC. /NEW/
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | |
|---|---|---|---|---|---|---|
| Revenue | $14.8M | $22.5M | $0 | $14.0M | $15.2M | $7.8M |
| Operating income | −$43.6M | $1.6M | −$69.2M | −$76.9M | −$59.4M | −$42.9M |
| Net income | −$29.4M | −$74,000 | −$73.9M | −$78.7M | −$61.6M | −$45.0M |
| Total assets | $441.6M | $160.3M | $16.6M | $162.1M | $105.3M | $99.0M |
| Total liabilities | $251.5M | $87.9M | $91.7M | $44.5M | $44.3M | $29.0M |
| Equity | $190.1M | $72.3M | −$293.5M | −$222.1M | −$145.6M | $70.0M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 31.3M | 52.4M | 48.2M | 43.5M | 33.2M | 24.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2018- Operating margin
- −293.8%
- Net margin
- −198.3%
- Return on equity
- −15.5%
- Return on assets
- −6.7%
- Return on capital (ROCE)
- −14.2%
- Liabilities / assets
- 57.0%
- Debt / equity
- 1.32×
- Book value / share
- $6.06
- Revenue growth (YoY)
- −33.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2018- Altman Z″ (distress)
- -3.79distress
- Accruals / assets
- 32.2%high accruals
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 5 warning● 0 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- High accruals — earnings-quality risk
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Bankruptcy or receivership · Unregistered equity sale · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Regulation FD disclosureApr 20, 2020
- Bankruptcy or receivership · Regulation FD disclosureApr 14, 2020
- Other material eventFeb 18, 2020
- Delisting / listing-standard noticeJan 8, 2020
- Entered a material agreement · Bankruptcy or receivership · Debt acceleration / triggering event · Director / officer change · Other material eventDec 27, 2019
- Other material eventNov 6, 2019
- Other material eventOct 24, 2019
- Director / officer change · Regulation FD disclosureSep 3, 2019
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.